We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 11, 2020

Zanubrutinib vs Ibrutinib in Symptomatic Waldenström Macroglobulinemia



Additional Info

A Randomized Phase 3 Trial of Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: The Aspen Study
Blood 2020 Jul 30;[EPub Ahead of Print], CS Tam, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, BE Wahlin, R Garcia-Sanz, H McCarthy, S Mulligan, A Tedeschi, J Castillo, J Czyz, C Fernández de Larrea, D Belada, E Libby, JV Matous, M Motta, T Siddiqi, M Tani, M Trneny, MC Minnema, C Buske, V Leblond, WY Chan, JY Schneider, S Ro, A Cohen, J Huang, MA Dimopoulos

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading